COgnitioN With VERiciGuat Evaluation in Heart Failure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06601465

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06601465
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06601465. Randomized; no masking; primary purpose treatment. Start 2025-06-03 (actual); primary completion 2028-07-16 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COgnitioN With VERiciGuat Evaluation in Heart Failure
Acronym
CONVERGE-HF
Condition
Heart Failure
Condition
Cognitive Impairment
Intervention (Drug)
Vericiguat
Lead sponsor
University of Alberta (class: other)
Collaborator
Ottawa Heart Institute Research Corporation (class: other)
Collaborator
Heart and Stroke Foundation of Canada (class: other)

Record details

Record id
cardio:ct-nct06601465
Content hash
9a023e147cd49bf48cb4859d6a5a2d7a2238b926385e1345a188eb6b0e94b18a